Nanoparticles dramatically improve effectiveness of antibacterial treatments
The U.S. Environmental Protection Agency should examine whether combined exposures to chemicals known as phthalates could cause adverse health effects in humans, says a new report from the National Research Council. In addition, this analysis, called a cumulative risk assessment, should consider other chemicals that could potentially cause the same health effects as phthalates, instead
Full Post: EPA should assess health risk of phthalates and other chemicals
Scientists at the University of Liverpool have developed a new technology which can dramatically improve the effectiveness of antibacterial treatments.
Drugs with the ability to dissolve have much stronger efficacy, however many drugs are insoluble. In order to compensate, drugs often need to be administered in higher doses. This increases the possibility of bacteria and other organisms mutating as the high doses make it easier for them to build resistance to the drugs. This leads to treatments becoming obsolete and the need for new medicines to be developed.
Chemists at the University of Liverpool working with IOTA NanoSolutions have now developed a new technology to produce nanoparticles of insoluble drugs that mimic the behaviour and the effectiveness of dissolved drugs.
Nanoparticles are man-made particles manufactured for use in a number of industries including the cosmetic and pharmaceutical industry; they can make materials stronger, lighter and cleaner.
Recent data has shown that in some cases, low concentrations of insoluble drugs in a nanoparticle form can be more active than previously thought, offering the potential to administer drugs in low dosages without reducing the effectiveness of the treatment. The new technology is allowing the scientists to develop new medicines by converting currently available drugs into a nanoparticle form. Antiparastitic drugs to treat malaria are also being developed in collaboration with the Liverpool School of Tropical Medicine.
Professor Steve Rannard, from the Department of Chemistry who is also co-founder and current Chief Scientific Officer of IOTA NanoSolutions, said: “Already our technology has shown the potential to improve a range of current medicines and may lead to treatments that prevent drug resistance. If our approach can deliver new antimalarial treatments, it may help to prevent millions of deaths per year and improve the lives of hundreds of millions of current malaria sufferers.”
This research is published in Nature Nanotechnology.
Three emerging technologies have the potential to significantly improve supplies of drugs to combat malaria, according to a report published today. With renewed efforts to eradicate malaria - a disease which kills up to one million people every year, most of them young children - the global demand for antimalarials is set to increase dramatically
Full Post: New technologies improve supplies of drugs to combat malaria
Looking at the retina in the eyes of patients with cerebral malaria has provided scientists with a vital insight into why malaria infection in the brain is so deadly. In a study funded by the Wellcome Trust and Fight for Sight and published in the Journal of Infectious Diseases, researchers in Malawi have shown for
Full Post: The retina reveals deadly secrets of malaria
Virginia Tech Intellectual Properties (VTIP) announces that the US Patent and Trademark Office has granted a patent for targets and methods to develop new drugs for malaria. For decades, scientists have been searching for a way to target malaria-causing parasites that have infected the human body. Researchers from the Virginia Biotechnology Institute (VBI) at Virginia
Full Post: U.S. patents granted to Virginia Tech for targets and methods to develop new drugs for malaria
This year, the U.S. Food and Drug Administration is expected to approve the first malaria drug to contain artemisinin, a wormwood derivative from China that has proven effective for malaria in Africa and Asia. Although there are only about 1,500 reported cases of malaria treated in this country each year, this approval would also make
Full Post: First artemisinin based malaria drug may meet resistance, expert says
The results of two new large scale trials show that the combination of dihydroartemisinin and piperaquine (DHA+PQP) not only is effective against uncomplicated malaria in a way which is comparable to other artemisinin-based combination therapies (ACTs), but it also protects patients against new infections for at least two months after treatment. The DHA/PQP combination is
Full Post: Combo malaria treatment dihydroartemisinin and piperaquine shows promise